• On 18 June 2026, Eli Lilly’s Lilly TuneLab announced a collaboration under which Charles River Laboratories will provide standardized nonclinical testing services to AI/ML-driven drug discovery companies using the platform.
• This arrangement links Charles River directly into an AI-enabled ecosystem built on decades of Lilly research data, potentially deepening its role in data-rich, next-generation preclinical research workflows.
• We’ll now examine how Charles River’s role in Lilly’s AI-powered TuneLab ecosystem could influence its investment narrative and long-term positioning.

We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Charles River Laboratories International Investment Narrative Recap

To invest in Charles River Laboratories, you need to believe its contract research and preclinical services remain essential as drug development becomes more complex and data intensive. The Lilly TuneLab collaboration ties Charles River into an AI driven discovery network, but it does not materially change the near term focus on stabilizing Discovery & Safety Assessment demand or the key risk that a faster shift toward non animal methods could pressure its core animal based testing revenues.

The recent MOU with MEDIPOST around cell therapy testing fits neatly alongside the TuneLab agreement, highlighting how Charles River is positioning itself around advanced, data rich modalities. Together, these partnerships speak to a catalyst many shareholders are watching closely: whether expanding capabilities in cell and gene therapies and AI enabled workflows can offset slower overall revenue growth and help the business return to sustainable profitability over time.

However, against this potential upside, investors should also recognize the growing risk that accelerated adoption of non animal testing methods could eventually reshape Charles River’s core market...

Charles River Laboratories International's narrative projects $4.4 billion revenue and $483.2 million earnings by 2028.

Uncover how Charles River Laboratories International's forecasts yield a $215.73 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Some of the most pessimistic analysts expected flat revenue near US$4.0 billion and only US$354.6 million of earnings by 2029, a view that contrasts sharply with the more balanced consensus and may be revisited as AI focused collaborations like TuneLab develop.

Explore 4 other fair value estimates on Charles River Laboratories International - why the stock might be worth as much as 55% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Charles River Laboratories International research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Charles River Laboratories International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Charles River Laboratories International's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.